Cipla Limited to collaborate with Kemwell Biopharma Private Limited a leading global CDMO. The collaboration aims to make cost-effective biotherapeutics. To achieve this, a joint venture business will be established with the intention of breaking into the respiratory biosimilars market. In accordance with the terms of the agreement, the joint venture will make use of Cipla and Kemwell's complementary competencies for clinical development, end-to-end product development, regulatory filings, manufacturing, and biopharmaceutical product commercialization. The combination of Kemwell's biologics knowledge with Cipla's respiratory capability will hasten the release of these vital drugs.
Sandroz, a subsidiary of Novartis, declared the acquisition of cephalosporin antibiotics business of GSK, to expand its portfolio in manufacturing antibiotics. Subject to the terms of the transaction, Sandoz would pay GSK USD 350 million at closing and up to a further milestone amount of USD 150 million. Subject to customary closing conditions, such as legal clearance, the transaction should be completed in the second half of 2021.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3640
Published Date: Jan 05, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing prevalence of RVF and increasing awareness about the disease are some of the major factors anticipated to drive the growth of the rift valley fever treatment market.
The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.
The major players in the market are of Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., Eli Lilly and Company, and others.
The medication segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.